Media Room

Stefanie Kutschmann, Good Manufacturing Practice Officer, Frankfurt, Germany

First quarter 2024 results

First quarter 2024 results were reviewed by management during a conference call with the financial community on April 25th. The presentation was followed by a Q&A session.

14:30 - 16:00 CET (8:30am – 10am EST)

Press releases

May 13, 2024
Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty
May 10, 2024
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
May 2, 2024
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations

Contact our media team

You are a journalist and have a question about Sanofi, please contact the Global Media relations team. Please note the contact details are only for journalists.

For any other request, please call the switchboard: +33 1 53 77 40 00


Declaration of extra-financial performance 2023 (ESG Report)
Download PDF
Half Year 2023 Financial Report XBRL Package
Download PDF
Half Year 2023 Financial Report
Download PDF
First quarter 2023 results
Download PDF